MY203853A - Crystalline salts of a b-raf kinase inhibitor - Google Patents
Crystalline salts of a b-raf kinase inhibitorInfo
- Publication number
- MY203853A MY203853A MYPI2020001994A MYPI2020001994A MY203853A MY 203853 A MY203853 A MY 203853A MY PI2020001994 A MYPI2020001994 A MY PI2020001994A MY PI2020001994 A MYPI2020001994 A MY PI2020001994A MY 203853 A MY203853 A MY 203853A
- Authority
- MY
- Malaysia
- Prior art keywords
- kinase inhibitor
- raf kinase
- crystalline salts
- crystalline
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577313P | 2017-10-26 | 2017-10-26 | |
| PCT/US2018/057792 WO2019084459A1 (en) | 2017-10-26 | 2018-10-26 | CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY203853A true MY203853A (en) | 2024-07-22 |
Family
ID=64277870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2020001994A MY203853A (en) | 2017-10-26 | 2018-10-26 | Crystalline salts of a b-raf kinase inhibitor |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11306086B2 (https=) |
| EP (2) | EP4245758A3 (https=) |
| JP (2) | JP7230041B2 (https=) |
| KR (1) | KR102820822B1 (https=) |
| CN (2) | CN111818924B (https=) |
| AU (2) | AU2018355528B2 (https=) |
| BR (1) | BR112020008248A2 (https=) |
| CA (1) | CA3080324A1 (https=) |
| ES (1) | ES2947411T3 (https=) |
| IL (1) | IL274027B2 (https=) |
| MX (1) | MX2020004148A (https=) |
| MY (1) | MY203853A (https=) |
| PH (1) | PH12020550485A1 (https=) |
| SG (1) | SG11202003635TA (https=) |
| WO (1) | WO2019084459A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019084459A1 (en) | 2017-10-26 | 2019-05-02 | Xynomic Pharmaceuticals, Inc. | CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR |
| JP2022069426A (ja) * | 2020-10-23 | 2022-05-11 | マイラン ラボラトリーズ リミテッド | テネリグリプチン２．５臭化水素酸塩のアモルファスを調製する方法 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| ATE273695T1 (de) | 2000-06-28 | 2004-09-15 | Smithkline Beecham Plc | Nassvermahlung |
| CA2546192C (en) * | 2003-11-17 | 2010-04-06 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
| GB0423554D0 (en) * | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| CN102206216B (zh) | 2005-06-22 | 2014-11-12 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
| EP2013218A2 (en) * | 2006-04-17 | 2009-01-14 | Arqule, Inc. | Raf inhibitors and their uses |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| WO2010042337A1 (en) | 2008-10-07 | 2010-04-15 | Merck Sharp & Dohme Corp. | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| ES2570569T3 (es) * | 2009-09-28 | 2016-05-19 | Hoffmann La Roche | Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso |
| US8889684B2 (en) * | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| TWI589576B (zh) | 2011-07-15 | 2017-07-01 | 諾華公司 | 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法 |
| SG10201907684PA (en) * | 2013-01-15 | 2019-10-30 | Aragon Pharmaceuticals Inc | Androgen receptor modulator and uses thereof |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| WO2016167340A1 (ja) | 2015-04-16 | 2016-10-20 | 日東電工株式会社 | Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物 |
| CN105801584B (zh) * | 2016-03-16 | 2019-03-05 | 中国药科大学 | 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
| WO2019084459A1 (en) | 2017-10-26 | 2019-05-02 | Xynomic Pharmaceuticals, Inc. | CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR |
-
2018
- 2018-10-26 WO PCT/US2018/057792 patent/WO2019084459A1/en not_active Ceased
- 2018-10-26 IL IL274027A patent/IL274027B2/en unknown
- 2018-10-26 BR BR112020008248-1A patent/BR112020008248A2/pt not_active IP Right Cessation
- 2018-10-26 EP EP23167989.5A patent/EP4245758A3/en not_active Withdrawn
- 2018-10-26 JP JP2020543248A patent/JP7230041B2/ja active Active
- 2018-10-26 KR KR1020207014962A patent/KR102820822B1/ko active Active
- 2018-10-26 ES ES18801183T patent/ES2947411T3/es active Active
- 2018-10-26 MX MX2020004148A patent/MX2020004148A/es unknown
- 2018-10-26 US US16/759,187 patent/US11306086B2/en active Active
- 2018-10-26 AU AU2018355528A patent/AU2018355528B2/en active Active
- 2018-10-26 CN CN201880081003.9A patent/CN111818924B/zh active Active
- 2018-10-26 EP EP18801183.7A patent/EP3700530B1/en active Active
- 2018-10-26 MY MYPI2020001994A patent/MY203853A/en unknown
- 2018-10-26 CA CA3080324A patent/CA3080324A1/en active Pending
- 2018-10-26 CN CN202310913355.9A patent/CN116942672B/zh active Active
- 2018-10-26 SG SG11202003635TA patent/SG11202003635TA/en unknown
-
2020
- 2020-04-24 PH PH12020550485A patent/PH12020550485A1/en unknown
-
2022
- 2022-02-17 AU AU2022201044A patent/AU2022201044B2/en active Active
- 2022-03-11 US US17/692,695 patent/US11753409B2/en active Active
-
2023
- 2023-02-15 JP JP2023021816A patent/JP2023062074A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550485A1 (en) | Crystalline salts of a b-raf kinase inhibitor | |
| PH12020550143A1 (en) | Salts of pyrrolotriazine derivatives useful as tam inhibitors | |
| IL281127A (en) | Pyrazolo[3,4-b]pyridine compounds as inhibitors of tam and met kinases | |
| ZA202205900B (en) | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer | |
| ZA202204284B (en) | Inhibitors of raf kinases | |
| JOP20190077A1 (ar) | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret | |
| PH12017501995A1 (en) | Solid forms of a compound modulating kinases | |
| TN2019000110A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| EA201070013A1 (ru) | СОЛИ ИНГИБИТОРА ЯНУС-КИНАЗЫ (R)-3-(4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА | |
| MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| PH12019501022A1 (en) | Pyrazolopyrimidine compounds and methods of use thereof | |
| EA201300997A1 (ru) | ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ | |
| MY190568A (en) | Carbazole derivatives | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| MX2017009600A (es) | Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero. | |
| EP3709998B8 (en) | N-[5-(imidazo[1,2-a]pyrimidin-2-yl)phenyl]-benzamide and -benzeneacetamide derivatives as tnf stimulators for the treatment of e.g. infectious diseases and cancer | |
| MY210039A (en) | Compounds, compositions, and methods for modulating cdk9 activity | |
| AR112040A1 (es) | Sal de n-(2,6-dietilfenil)-8-({4-[4-(dimetilamino)piperidin-1-il]-2-metoxifenil}amino)-1-metil-4,5-dihidro-1h-pirazolo[4,3-h]quinazolina-3-carboxamida, su preparación, y las formulaciones que la contienen | |
| EA201990940A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
| UA124942C2 (uk) | Спосіб одержання енантіомерів пірліндолу та їхніх солей | |
| EA201990385A1 (ru) | Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение | |
| EA201990939A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
| AU2017903305A0 (en) | DERIVATIVES OF 4-(IMIDAZO[1,2-a]PYRIDIN-3-YL)PYRIMIDIN-2-AMINE AND THEIR USE AS INHIBITORS OF PROTEIN KINASES | |
| EA202091616A2 (ru) | ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |